{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:05:25Z","timestamp":1787371525003,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04156-6","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:56:24Z","timestamp":1747302984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI\u2122 healthcare database"],"prefix":"10.1186","volume":"26","author":[{"given":"Miguel G.","family":"Uriol-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank R.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John N.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0ngels","family":"Comas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gasteyger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tomazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"4156_CR1","doi-asserted-by":"crossref","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2017;91(3):539\u201351.","DOI":"10.1016\/j.kint.2016.10.005"},{"issue":"10095","key":"4156_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396.","journal-title":"Lancet"},{"issue":"1","key":"4156_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, et al. Atypical Hemolytic-Uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4\u201321.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"4156_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40273-019-00862-w","volume":"38","author":"M Ryan","year":"2020","unstructured":"Ryan M, Donato BMK, Irish W, Gasteyger C, L\u2019Italien G, Laurence J. Economic impact of Early-in-Hospital diagnosis and initiation of Eculizumab in atypical haemolytic uraemic syndrome. PharmacoEconomics. 2020;38(3):307\u201313.","journal-title":"PharmacoEconomics"},{"key":"4156_CR5","unstructured":"Woodward LB, Shah L. Kamal. aHUS Diagnosis Process: Patients\u2019 experience of specialist care and the diagnosis decision. 2022 [Available from: https:\/\/www.ahusallianceaction.org\/wp-content\/uploads\/2022\/02\/aHUS-Diagnosis-Process-Patients-experience-of-specialist-care-and-the-diagnosis-decision-1.pdf"},{"issue":"3","key":"4156_CR6","first-page":"216","volume":"31","author":"MN Yenerel","year":"2014","unstructured":"Yenerel MN. Atypical hemolytic uremic syndrome: differential diagnosis from TTP\/HUS and management. Turk J Haematol. 2014;31(3):216\u201325.","journal-title":"Turk J Haematol"},{"issue":"10 Suppl 17","key":"4156_CR7","first-page":"1","volume":"10","author":"J Laurence","year":"2012","unstructured":"Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(10 Suppl 17):1\u201312.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"4156_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/trf.13359","volume":"56","author":"NT Connell","year":"2016","unstructured":"Connell NT, Cheves T, Sweeney JD. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. Transfusion. 2016;56(2):354\u20139.","journal-title":"Transfusion"},{"key":"4156_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/asheducation.V2012.1.604.3798564","volume":"2012","author":"JN George","year":"2012","unstructured":"George JN, Al-Nouri ZL. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematol Am Soc Hematol Educ Program. 2012;2012:604\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"4156_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"J Vande Walle","year":"2017","unstructured":"Vande Walle J, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of Eculizumab treatment. J Nephrol. 2017;30(1):127\u201334.","journal-title":"J Nephrol"},{"issue":"4","key":"4156_CR11","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157\u201364.","journal-title":"Lancet Haematol"},{"issue":"1","key":"4156_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jth.13882","volume":"16","author":"A Li","year":"2018","unstructured":"Li A, Khalighi PR, Wu Q, Garcia DA. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018;16(1):164\u20139.","journal-title":"J Thromb Haemost"},{"key":"4156_CR13","doi-asserted-by":"publisher","first-page":"9180810","DOI":"10.1155\/2019\/9180810","volume":"2019","author":"E Lu","year":"2019","unstructured":"Lu E, Moore W. The PLASMIC score May be useful in the early diagnosis of Complement-Mediated thrombotic microangiopathy via early exclusion of thrombotic thrombocytopenic Purpura. Case Rep Med. 2019;2019:9180810.","journal-title":"Case Rep Med"},{"issue":"3","key":"4156_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311.","journal-title":"Kidney Int"},{"issue":"5","key":"4156_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061\u201373.","journal-title":"Kidney Int"},{"issue":"23","key":"4156_CR16","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"key":"4156_CR17","doi-asserted-by":"crossref","unstructured":"Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J. 2018.","DOI":"10.1093\/ckj\/sfy035"},{"issue":"1","key":"4156_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125.","journal-title":"BMC Nephrol"},{"issue":"6","key":"4156_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome Na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396.","journal-title":"Kidney Int"},{"key":"4156_CR20","unstructured":"PINC AI\u2122 Applied Sciences PI. PINC AI\u2122 Healthcare Database: Data that informs and performs (White Paper). 2022 [Available from: https:\/\/offers.premierinc.com\/PINC-AI-Healthcare-Database-White-Paper-LP.html"},{"key":"4156_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","volume":"5","author":"R Trevethan","year":"2017","unstructured":"Trevethan R, Sensitivity. Specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307.","journal-title":"Front Public Health"},{"key":"4156_CR22","doi-asserted-by":"publisher","first-page":"893273","DOI":"10.3389\/fmed.2022.893273","volume":"9","author":"CH Lee","year":"2022","unstructured":"Lee CH, Huang YC, Li SS, Hsu YT, Chen YP, Chen TY. Application of PLASMIC score in risk prediction of thrombotic thrombocytopenic purpura: Real-World experience from a tertiary medical center in Taiwan. Front Med (Lausanne). 2022;9:893273.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"4156_CR23","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/trf.15954","volume":"60","author":"K Paydary","year":"2020","unstructured":"Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis. Transfusion. 2020;60(9):2047\u201357.","journal-title":"Transfusion"},{"issue":"1","key":"4156_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/bjh.18123","volume":"198","author":"MS Reddy","year":"2022","unstructured":"Reddy MS, Newsom N, Sakurai S, Park SY, Reisch J, Sarode R. Performance of the PLASMIC score is improved with a positive score defined as \u2265\u20095 and with the inclusion of neurological symptoms. Br J Haematol. 2022;198(1):e1\u20133.","journal-title":"Br J Haematol"},{"issue":"2","key":"4156_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ekir.2021.11.009","volume":"7","author":"N Fage","year":"2022","unstructured":"Fage N, Orvain C, Henry N, Mellaza C, Beloncle F, Tuffigo M, et al. Proteinuria increases the PLASMIC and French scores performance to predict thrombotic thrombocytopenic Purpura in patients with thrombotic microangiopathy syndrome. Kidney Int Rep. 2022;7(2):221\u201331.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4156_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/trf.16188","volume":"61","author":"A Liu","year":"2021","unstructured":"Liu A, Dhaliwal N, Upreti H, Kasmani J, Dane K, Moliterno A, et al. Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion. 2021;61(1):266\u201373.","journal-title":"Transfusion"},{"issue":"1","key":"4156_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12882-017-0727-y","volume":"18","author":"T Sakari Jokiranta","year":"2017","unstructured":"Sakari Jokiranta T, Viklicky O, Al Shorafa S, Coppo R, Gasteyger C, Macia M, et al. Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrol. 2017;18(1):324.","journal-title":"BMC Nephrol"},{"issue":"2","key":"4156_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ajcp\/aqv086","volume":"145","author":"LA Williams","year":"2016","unstructured":"Williams LA, Marques MB. Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs). Am J Clin Pathol. 2016;145(2):158\u201365.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"4156_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jha2.154","volume":"2","author":"C Dos Santos","year":"2021","unstructured":"Dos Santos C, Paiva J, Romero ML, Agazzoni M, Kempfer AC, Rotondo S, et al. Thrombotic microangiopathies: first report of 294 cases from a single institution experience in Argentina. EJHaem. 2021;2(2):149\u201356.","journal-title":"EJHaem"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04156-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:56:27Z","timestamp":1747302987000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04156-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient-level data included in this study were evaluated and approved by the Institutional Review Board or Independent Ethics Committee, and the study was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"All participants provided informed consent prior to enrolling in the clinical trials included in this study; due to the de-identified nature of the PINC AI\u2122 database, consent was not required for these patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Miguel Giovanni Uriol-Rivera is a consultant of Alexion, AstraZeneca Rare Disease, including expert testimony fees; a receipt of honoraria from Alexion, AstraZeneca Rare Disease, has participated in advisory boards for Alexion, AstraZeneca Rare Disease and has also received honoraria from GlaxoSmithKline. Frank R Ernst was an employee of CTI Clinical Trial and Consulting Services, Inc, who were contracted by Alexion, AstraZeneca Rare Disease, at the time of the study. John N Booth III was an employee of CTI Clinical Trial and Consulting Services, Inc, who were contracted by Alexion, AstraZeneca Rare Disease to conduct the current study, at the time of the study. \u00c0ngels Comas is a current employee and stakeholder of Alexion, AstraZeneca Rare Disease. Christoph Gasteyger is a current employee and stakeholder of Alexion, AstraZeneca Rare Disease. Ioannis Tomazos was an employee of Alexion, AstraZeneca Rare Disease at the time this study was conducted. Ching Lum was an employee of Alexion, AstraZeneca Rare Disease at the time this study was conducted. Yan Wang is a current employee and stakeholder of Alexion, AstraZeneca Rare Disease. Ana I \u00c1vila has received honoraria from, and participated in advisory boards for Alexion, AstraZeneca Rare Disease, and is a recipient of honoraria from GlaxoSmithKline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}